UI 056
Alternative Names: UI-056Latest Information Update: 28 May 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Rheumatoid-arthritis in South Korea (Controlled release)
- 30 Apr 2020 UI 056 is available for licensing as of 30 Apr 2020. https://www.kup.co.kr/research/innovation_main.htm